Second-Generation Antidepressants for Treating Adult Depression—An Update
IImmediate-Release Versus Extended-Release Formulations of Second-Generation Antidepressants for Adults With MDD
There were five head-to-head trials that investigated the comparative efficacy of daily versus weekly dosing and immediate-release versus extended-release formulations. Two of these trials compared fluoxetine daily with fluoxetine weekly; two good-quality trials assessed paroxetine IR (immediate release) versus paroxetine CR (controlled release); and one trial compared venlafaxine IR with venlafaxine XR (extended release). There were no studies on other medications, such as bupropion or fluvoxamine, that are available as both immediate-release and extended-release formulations.
- Five head-to-head trials investigated the comparative efficacy of daily versus weekly dosing and immediate-release versus extended-release formulations.
- Two randomized controlled trials (RCTs) reported similar rates of maintenance of response and relapse for patients treated with fluoxetine daily or fluoxetine weekly during the continuation phase of therapy for major depressive disorder (MDD). The strength of evidence is moderate.
- One RCT and a pooled analysis of two identical RCTs did not find any differences in response rates in patients treated with paroxetine IR or paroxetine XR for acute-phase MDD. The strength of evidence is moderate.
- One RCT reported higher response rates for patients on venlafaxine XR than those on venlafaxine IR. The strength of evidence is low.
Keywords: extended release | remission | response | second-generation antidepressant | immediate release
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.